Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
The Sarcomere01:08

The Sarcomere

17.1K
A sarcomere is a microscopic segment repeating in a myofibril. The sarcomere fundamentally consists of two main myofilaments: thick filaments called myosin and thin filaments called actin. These filaments interact by sliding past each other in response to stimulus. In addition to myosin and actin, several other proteins, such as tropomyosin, troponin, titin, nebulin, myomesin, α-actinin, and dystrophin, play crucial roles in regulating, structuring, and functioning of the sarcomere.
Each...
17.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Skin Cancer01:30

Skin Cancer

6.3K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study.

Oncology and therapy·2026
Same author

Response to Letter to the Editor: Comments on "Surgery for Retroperitoneal Soft Tissue is Safe following Multimodal Treatment with Regional Hyperthermia".

Annals of surgical oncology·2026
Same author

Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial.

Cancer·2026
Same author

Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

The New England journal of medicine·2026
Same author

Evaluation of RECIST v1.1 for predicting overall survival in sarcoma patients with pulmonary metastasis.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

[Digital patient journey after radiological diagnostics : Patient portals-what comes after the examination?]

Radiologie (Heidelberg, Germany)·2026
Same journal

[Before the examination: digital check-in].

Radiologie (Heidelberg, Germany)·2026
Same journal

[National infrastructures and the European Health Data Space].

Radiologie (Heidelberg, Germany)·2026
Same journal

[The digital patient journey : Performing radiological examinations].

Radiologie (Heidelberg, Germany)·2026
Same journal

Radiologie (Heidelberg, Germany)·2026
Same journal

Radiologie (Heidelberg, Germany)·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 24, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.4K

肉腫：臨床的導入

Lars H Lindner1

  • 1Zentrum für Knochen- und Weichteiltumoren (SarKUM), LMU Klinikum, Medizinische Klinik III, Marchioninistr. 15, 81377, München, Deutschland. lars.lindner@med.uni-muenchen.de.

Radiologie (Heidelberg, Germany)
|February 23, 2026
PubMed
まとめ
この要約は機械生成です。

放射線科的診断は肉腫の治療計画に不可欠です。全身MRIを含む画像検査の正確な解釈は、転移の検出と治療効果の評価に役立ち、放射線被曝を最小限に抑えながら腫瘍学的安全性を確保します。

キーワード:
集学的治療術前療法偽進行肉腫画像診断全身MRI

さらに関連する動画

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

関連する実験動画

Last Updated: Feb 24, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.4K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

科学分野:

  • 腫瘍学
  • 放射線科
  • 医用画像

背景:

  • 肉腫は結合組織の不均一な悪性腫瘍です。
  • 正確な診断と治療計画には、専門的な放射線科の専門知識が不可欠です。
  • 放射線科医は、疑わしい所見を特定し、専門センターへの紹介を促進します。

研究 の 目的:

  • 肉腫管理における放射線科診断の重要な役割を強調すること。
  • 肉腫サブタイプに基づく個別化された画像戦略の必要性を強調すること。
  • 治療効果の評価およびフォローアップ中の課題に対処すること。

主な方法:

  • 様々な肉腫サブタイプの画像戦略のレビュー。
  • 骨転移の検出のための全身MRI（例：粘液様脂肪肉腫）の議論。
  • 術前療法における偽進行と真の進行の区別における課題の分析。

主要な成果:

  • 画像検査の正確な解釈は、肉腫の治療計画における最初のステップです。
  • 全身MRIのような個別化された画像戦略は、特定のサブタイプに不可欠です。
  • 治療関連の変化と腫瘍進行を区別することは、重要な課題です。

結論:

  • 放射線科医は、肉腫の早期発見、紹介、および治療計画の中心です。
  • 適切な画像戦略はサブタイプに依存し、効果的な管理に不可欠です。
  • 肉腫のフォローアップにおいて、腫瘍学的安全性と放射線被曝のバランスをとることが最も重要です。